Santosh Tiwari Email and Phone Number

• Technical and strategic lead for mental health disorders and biosimilars • Develop and implement peri and post launch comprehensive evidence generation plans (clinical, economic, and humanistic evidence) that inform and contribute to the overall program strategies for one or more assets across mental health disorders • Work closely with the development counterpart, formulate and update the recommended GHEOR strategies (GVPs, GVDs, etc)• Enhance the team’s capabilities by coaching mentoring, and succession planning

• Partner with the global and regional teams for the development of HEOR strategies for value demonstration and product differentiation across Neuroscience and Global Health• Cross-functional alignment with various functions including Medical Affairs, commercial teams, etc• Planning and executing continuous improvement projects to achieve operational excellence• Line manage a team of 12 associates (senior analysts, managers, senior managers, and Team Leader) and enhance the team’s capabilities by coaching mentoring, and succession planning• Key Achievements: o Conceived, led, and delivered key RWE publications for post-launch assets (Kesimpta and Aimovig)o Partnered with the cross-functional team for the development of an integrated evidence plan for Remibruitnib indicated for MS

• Partner with Therapeutic Area Heads, HEOR, and Market Access Directors for the strategic development and execution of HEOR strategies to support the access and reimbursement of Neuroscience and Global Health assets • Lead the development of pre-launch, launch, and post-launch studies • Lead key quality of care initiative targeted at improving the healthcare system within the MS space• Provide evidence and strategic inputs for the reimbursement of Kesimpta across key markets (UK, France, Ireland), Mayzent (Lithuania), Aimovig (English West Africa), and (re)negotiations of Aimovig in the UK (NICE)• Expertise in analyzing, interpreting, and converting clinical and HEOR data into high-quality, peer-reviewed publications• Mentor and manage a team of 10 analysts and managers. Manage resource allocation and capacity and ensure work allocated to the team is completed in a timely manner and with high quality standards• Key Achievements: o Led and delivered SLRs for HTA submissions to Ireland and France (Kesimpta), Japan (Zolgensma), and NICE/SMC (Aimovig)o Led and delivered SLRs on MS Tx guidelines and Unmet needs in MSo Led the development of global value dossiers for Kesimpta and Aimovig and early global value dossiers for Huntington’s disease and MDD/TRDo Led the development of a comparator outcomes profile for malaria

• Collaborated with cross-functional leaders across Medical Affairs, Market Access, and Real-World Evidence team to maximize evidence generation efforts to optimize launch and sustained reimbursement throughout the product lifecycle• Provided HEOR inputs to other functions such as clinical development and marketing to support favorable pricing and reimbursement potential for new products• Developed, executed, and disseminated pre-launch, launch, and post-launch HEOR and RWE deliverables including literature reviews, network meta-analysis, global value dossiers, claims-, EHR-, and registry-based studies• Managed and oversaw a team of 10 analysts and managers. Managed resource allocation and capacity, and ensured seamless delivery of high-quality projects

• Led the RWE strategy and evidence-generation team• Key achievements: o Evidence generation to support the Development Decision Point for migraine and systemic lupus erythematosus (targeted reviews to support PRO strategy and value proposition) and post-launch studies for multiple therapeutic areas (claims-based analysis, and targeted and systematic literature reviews)• Mentor and manage a team of 15 analysts and medical writers. Responsible for operating, resourcing, and managing HEOR activities• Manage stakeholder relations and provide ongoing updates and collate and act upon client feedback

• Led HEOR strategy and evidence generation projects for pipeline and launch assets for adrenal insufficiency, acute bacterial skin and skin structure infections (ABSSSI), adult lower and upper limb spasticity (ALL & AUL), and acute lymphoblastic leukemia• Key achievements:o Evidence generation to support Development Decision Point for ABSSSI (targeted reviews and gap analysis)o Evidence generation to support the PBAC submission of Dysport indicated for AUL and ALL (systematic review and Network Meta-Analysis)o Supported the preparation and submission of Alkindi HTA dossier for Germany • Mentored and managed a team of 10 analysts and subject matter experts• Led publication activities

• Global point of contact for all HEOR and real-world evidence projects• Led planning, execution, and dissemination of HEOR & real-world evidence deliverables (claims-based analysis, and targeted- and systematic literature reviews)• Key achievements:o Led post-launch HEOR and real-world studies for multiple indications including ADHD, migraine, COPD, herpes zoster, systemic lupus erythematosus, chronic lymphocytic leukemia, acute lymphocytic leukemia, metastatic breast cancer• Mentored and managed a team of 15 analysts and medical writers. Responsible for resourcing and managing HEOR and real-world evidence activities• Managed stakeholder relations and provided ongoing updates and collated and acted upon client feedback

Executed HEOR and real-world evidence studies including literature reviews, HEOR reports, slide decks, global value dossiers, and publications (abstracts, posters, and manuscripts) for various indications

• Delivered scientific publications (abstracts, posters, slide decks, manuscripts, and narrative and systematic reviews) for the respiratory franchise• Developed a broad range of medical education deliverables (publication alerts, symposium presentations, advisory board meetings, and other on-site congress-related activities)• Responsible for liaising with internal stakeholders (medical communication leaders, Brand Directors, Global Medical Affairs Directors, and Global Brand Medical Director) and external stakeholders (key opinion leaders) for publication strategies

• Planned and executed research experiments on association and invasion of bladder epithelial cells by uropathogenic Escherichia coli and endothelial Nitric Oxide Synthase (eNOS) activation• Worked on establishing stable cell lines of bladder vascular endothelial cells expressing eNOS

• Instrumental in designing, coordinating, and working out strategies for the implementation of the research project• Led and conducted study operations through a team of Research and Project Assistants, liaison with vendors• Orchestrated the projects independently from project initiation to delivery• In addition, the duties also included compilation of the raw data, interpretation, and scripting manuscript for publication in various journals of National and International repute